Summary The cardiotoxicity of 5-fluorouracil (FU) was attributed to impurities present in the injected vials. One of these impurities was identified as fluoroacetaldehyde which is metabolised by isolated perfused rabbit hearts into fluoroacetate (FAC), a highly cardiotoxic compound. FAC was also detected in the urine of patients treated with FU. These impurities were found to be degradation products of FU that . However, the precise biochemical mechanism underlying this toxic side-effect still remains unknown even if the metabolic pathways of FU have now been largely elucidated (Heidelberger et al., 1983) . The cytotoxic activity of this drug stems from the anabolic pathway that leads to fluoronucleosides (FNUCs) then fluoronucleotides (FNUCt). The degradative pathway of FU biotransformation is called the catabolic pathway and mainly leads to a-fluoro-p-alanine (FBAL), an a-fluoro-13-amino-acid which closely resembles the natural P-amino-acid, 0-alanine. P-alanine is converted into acetate which enters the Krebs cycle and undergoes a metabolic conversion to citrate. By analogy with the natural substrate, it has been suggested but never demonstrated that FBAL might be transformed into fluoroacetate (FAC) (Philips et al., 1959; Koenig & Patel, 1970; Matsubara et al., 1980) . FAC is known to be a highly cardiotoxic and neurotoxic poison. Indeed, it also enters the Krebs cycle, is then transformed into fluorocitrate (FC) which inhibits citrate metabolism resulting in accumulation of intracellular citrate (Pattison & Peters, 1966) (Figure  1 ).
5-fluorouracil (FU) is widely used alone or in combined protocols in the treatment of various malignancies including gastrointestinal, breast and head and neck cancer. Common clinical adverse reactions include myelosuppression, diarrhea and mucositis. The cardiotoxicity of FU which was first reported in 1975 (Dent & McColl, 1975) was thought to be an infrequent, albeit severe, toxic side-effect. The incidence of FU cardiotoxicity was reported to be 1.6% in a retrospective study of 1,083 patients receiving FU in various protocols (Labianca et al., 1982) . However, over the last decade, a number of retrospective or anecdotal reports have pointed to a higher incidence of FU-related complications in patients receiving high doses of FU. Incidences of 6.5% (de Forni et al., 1990) , and 7.9% have been recently reported. In an analysis of 38 cases of FU cardiotoxicity in the literature, Collins and Weiden (1987) found that 26% of the patients who experienced cardiac events during FU chemotherapy either died or were severely disabled. Few studies have been designed to assess prospectively the risk of FU cardiotoxicity. In 76 patients given cisplatin in combination with a continuous i.v. infusion of FU with regular clinical and ECG examination, Eskilsson et al. (1988) observed adverse cardiac events (chest pain, arrythmia, ECG changes) in 14 patients (18%). By continuous ECG monitoring in 25 patients receiving a similar protocol, Rezkalla et al. (1989) observed ischemic ECG changes in 68% of patients during treatment vs 24% prior to FU administration. In 281 patients receiving a continuous i.v. infusion of high doses of FU, cardiac events occurred in 26 patients (9.3%) and the lethality rate was 2.5% (de Forni et al., 1991) .
Various hypotheses including ischemia secondary to coronary artery spasm, interaction of FU with the coagulation system, immunoallergic phenomena, direct toxicity of FU on the myocardium have been proposed to explain the cardiotoxicity of this drug (Freeman & Costanza, 1988; . However, the precise biochemical mechanism underlying this toxic side-effect still remains unknown even if the metabolic pathways of FU have now been largely elucidated (Heidelberger et al., 1983) . The cytotoxic activity of this drug stems from the anabolic pathway that leads to fluoronucleosides (FNUCs) then fluoronucleotides (FNUCt). The degradative pathway of FU biotransformation is called the catabolic pathway and mainly leads to a-fluoro-p-alanine (FBAL) , an a-fluoro-13-amino-acid which closely resembles the natural P-amino-acid, 0-alanine. P-alanine is converted into acetate which enters the Krebs cycle and undergoes a metabolic conversion to citrate. By analogy with the natural substrate, it has been suggested but never demonstrated that FBAL might be transformed into fluoroacetate (FAC) (Philips et al., 1959; Koenig & Patel, 1970; Matsubara et al., 1980) . FAC is known to be a highly cardiotoxic and neurotoxic poison. Indeed, it also enters the Krebs cycle, is then transformed into fluorocitrate (FC) which inhibits citrate metabolism resulting in accumulation of intracellular citrate (Pattison & Peters, 1966) (Figure  1 ).
Having at our disposal a powerful method for studying the metabolism of fluorinated drugs, especially fluoropyrimidines (Malet-Martino et al., 1990) , we explored the possibility of a direct toxic effect of FU or one of its metabolites on the mycocardium using fluorine-19 nuclear magnetic resonance ('9F NMR) and the isolated perfused rabbbit heart (IPRH) model. We also report in this paper the results of the '9F NMR analysis of biofluids from patients treated with FU. We demonstrate that a degradation compound of FU, resulting from the storage of this drug in alkaline conditions and found in the injected vials, is responsible for the cardiotoxicity of this antineoplastic drug since it is metabolised into FAC.
Materials and methods

Materials
Commercial FU Roche vials from France (50 mg FU ml-' of an aqueous solution buffered with Tris, pH = 8.5), Germany (25 mg FU ml-' of an aqueous NaOH solution, pH = 8.5), Great Britain (25 mg FU ml-I of an aqueous NaOH solution, pH = 8.5), USA (50 mg FU ml-of an aqueous NaOH solution, pH = 9.2) and a commercial US generic from SoloPak Laboratories (50 mg FU ml-' of an aqueous NaOH solution, pH = 9.1) were used. , and by spiking with authentic standards. The signals of FAC, fluoroacetaldehyde (Facet), its condensation product with Tris (Facet-Tris) were unambiguously assigned by adding the authentic compounds and recording the '9F NMR spectra with and without proton decoupling.
The concentrations of the fluorinated metabolites were measured by comparing the expanded areas of their respective NMR signals with that of sodium parafluorobenzoate. The areas were determined by weighing the cut out peaks. (Table II) . The amount of intramyocardial citrate was measured in isolated hearts without perfusion (n = 5), in isolated hearts perfused with a blank perfusate, i.e., without FU, during 1 h 30 (n = 4) or during 4 h (n = 2). Since the values were similar, the mean of the 11 experiments was taken as the control value, bSignificant at P < 0.025 compared with FU (Tris) at 25 or 45 mg kg-' b.w. and at P< 0.0005 compared with FU (Tris) at 90 or 180 mg kg-I b.w., cSignificant at P < 0.0005 vs control hearts, dNot significant compared with FU (Tris) at 25 mg kg-' b.w., significant at P < 0.01 compared with FU (Tris) at 45, 90 or 180 mg kg-' b.w., 0Not significant compared with FU (Tris) at 45 mg kg-' b.w., significant at P < 0.005 compared with FU (Tris) at 90 mg kg-' b.w., and at P < 0.0005 compared with FU (Tris) at 180 mg kg-' b.w., 'Significant at P < 0.005 compared with FU (Tris) at 45, 90, or 180mg kg-' b.w., "Not significant compared with FU (Tris) at 90mg kg-' b.w., significant at P <0.01 compared with FU (Tris) at 180 mg kg-' b.w., hNot significant compared with FU (Tris) at 90 mg kg-' b.w., significant at P < 0.05 compared with FU (Tris) at 180 mg kg-' b.w., 'Not significant compared with FU (Tris) at 180 mg kg-' b.w., Assuming that the concentration of Tris in a FU Roche vial is 84.7 mg ml-' (Matsubara et al., 1980) What is the origin of FAC? We first surmised that it derived from the metabolic transformation of FBAL (Figure 1) of heart perfusates. FAC was not detected. FAC was therefore assumed to be formed via a metabolic process.
Various other experiments were conducted to verify that impurity(ies) was(were) the precursor of FAC and the causative factor of FU cardiotoxicity. No cardiotoxic symptoms were observed during the 4 h of perfusion of IPRH treated with FU Sigma at 25 or 180 mg kg-' b.w., a powder that we dissolved in Tris buffer and that contained no fluorinated impurities (Table II) . Furthermore, there was no elevation in citrate levels with respect to the control (P>0.1). For both doses, small signals of FUrd, FUPA, FBAL, FUH2 were observed in the '9F NMR spectra of the perfusates. The signal of FAC was undetected. At 180mg FU kg-' b.w., we also observed a signal at -133.3 ppm corresponding to an unknown metabolite.
When vials of FU (Tris) Roche were treated in acidic conditions, FU precipitated and the '9F NMR spectrum of the powder after its redissolution in Tris buffer showed no fluorinated impurity. IPRH were treated with this 'purified' solution at 180 mg FU kg-' b.w. No symptoms of cardiotoxicity appeared during the 4 h of perfusion. There was no significant intramyocardial accumulation of citrate (P> 0.05 vs control) and FAC was not detected in the perfusates (Table II) .
The fact that the cardiotoxicity was due to impurity(ies) in FU Roche vials was confirmed by a last experiment with a sample of FU powder that Hoffmann-La Roche sent us and that we dissolved in Tris buffer immediately before the experiment. No fluorinated impurities were observed in the '9F NMR spectrum of this solution. There was no evidence of cardiotoxicity, nor any rise in intramyocardial citrate (4 yg g-I of heart) and no detectable FAC in perfusates after treatment of IPRH with this solution at 180 mg FU kg-' b.w.
Therefore, FAC must have come from the metabolic transformation of degradation compound(s) contained in vials of FU Roche that is(are) formed during the storage of the solution.
Identification of the precursor of FAC in FU (Tris) Roche vials We noticed that the intensity of the signal at -159.7 ppm relative to those of the signals at -122.3 and -125.9 ppm was higher in the '9F NMR spectra of FU (Tris) Roche vials than in those of perfusates of IPRH (compare Figures 2a and  2b) . FAC was therefore assumed to be derived essentially from the metabolic conversion of the compound resonating at -159.7 ppm.
The simplest hypothesis was that FAC resulted from metabolic oxidation of Facet. We thus synthesised this compound by oxidation of fluoroethanol. In H20, it exists as the aldehyde hydrate 1. It reacts with Tris to give a compound (Facet-Tris) whose structure was determined as the oxazolidine 2, which on acid hydrolysis gives Facet hydrate 1 in the following reaction:
The compound resonating at -159.7 ppm was extracted from vials of FU (Tris) Roche. It had identical spectroscopic characteristics to those of the oxazolidine 2.
When IPRH were treated with this compound at an equivalent dose to that that would have been injected if hearts were treated with FU Roche vials at 180 mg kg-' b.w., ventricular arrest occurred at 140 ± 15 min, citrate levels rose significantly (P<0.0005 vs control) and FAC was the main compound detected in the '9F NMR spectra of perfusates in a similar amount to that found in perfusates of hearts treated with FU (Tris) Roche vials at 180mg kg-' b.w. (P>0.1) (Table II) . The other small signals were unmetabolised oxazolidine 2 and Facet hydrate 1. Therefore, a depot form of Facet that is converted into FAC by isolated perfused hearts is present in vials of FU (Tris) Roche.
'9F NMR analysis of urine from patients treated with FU (Tris) Roche vials Thirty-three urine samples from 15 patients (six with cardiotoxic symptoms, nine without) treated with continuous i.v. infusion of FU (Tris) Roche were analysed. Unmetabolised FU and its classical catabolites (FUH2, FUPA, FBAL and its derivatives, F-) were observed in the '9F NMR spectra. In addition, FAC was detected in all urine samples analysed irrespective of any reported cardiotoxicity. In some samples, it was also possible to detect the signals in the -120 ppm area found in FU vials. The signal of the oxazolidine 2 was not observed. A low signal of Facet hydrate was detected in some samples. A resonance with a 6 varying between -153.0 and -154.5 ppm and attributed to a compound resulting from the chemical interaction of Facet with an unknown urinary component was observed in most samples. The quantitative analysis of urine samples from six patients showed that the ratio FAC excreted in 24 h/FU catabolites excreted in 24 h increased during the treatment for five patients (Figure 3 ). NMR spectra (Figure 4b) . The spectra were, however, more complex than those of the FU (Tris) vials (compare Figures  2b and 4b) . F-was the main impurity (representingt0.3-1.5 mole% relative to FU) but signals from approximately 50 different fluorinated substances could be observed at individual concentrations of approximately 0.005-0.1 mole%. The FU total of the combined fluorinated impurities came to between 1 and 3 mole%. Since these vials do not contain Tris, any Facet present should be in the form of the hydrate 1 and not the oxazolidine 2. We therefore sought Facet hydrate. There was a marked increase in the signal at -155.16 ppm after spiking the sample with Facet hydrate, although more detailed examination of this signal (which represents %0.0I -0.05 mole%) showed two close signals (Au;)3 Hz), one of which was Facet hydrate (Figure 4b insert) . This impurity could not therefore be quantified accurately.
IPRH were treated with the content of these vials at 180 mg FU kg-' b.w. Ventricular arrest occurred at various times even in experiments with vials of the same origin (Table II) . However, we consistently observed episodes of arrythmia after around 2 h. The German FU led to a marked rise in intramyocardial citrate, comparable to that observed with FU (Tris) Roche. There was a lower but significant rise in citrate levels after treatment with the contents of the American and English FU vials (P< 0.0005 vs control). (Mukherjee & Heidelberger, 1960 The lack of symptoms of cardiotoxicity and the absence of FAC in perfusates of hearts treated with FU powder (Sigma, Roche) dissolved just before use suggested that the origin of FAC had to be searched in the injected vials. FU vials contain fluorinated impurities whether NaOH or Tris solutions are used to dissolve the drug (Figures 2b and 4b) . Fluoride ion was found in both types of vial. A critical impurity was identified in the FU Tris vials, namely the oxazolidine of Facet. It is known that Tris reacts readily with propionaldehyde or aldoifosfamide to produce the corresponding oxazolidines (Borch & Getman, 1984; Zon et al., 1984) . We demonstrated by synthesis and isolation of this impurity and with conventional spectroscopic techniques that Tris also reacts with Facet to give the fluorinated oxazolidine 2. Injected into IPRH, it is metabolised into Facet and FAC. Thus, a depot form of Facet is present in FU (Tris) vials. It was noteworthy, however, that the ventricular arrest induced by the FU (Tris) Roche vials injected into IPRH at a dose of 180 mg FU kg-' b.w. occurred significantly earlier (P < 0.0005) than that induced by the oxazolidine 2 injected alone at a dose equivalent to that injected with FU Tris vials for a dose of 180mg FU kg-' b.w. (70 and 140 min respectively).
Since a freshly made up solution of FU did not induce symptoms of cardiotoxicity under our experimental conditions, it is likely that the impurities giving signals at -122.3 and -125.9 ppm have some responsibility for the toxicity although probably not via FAC since the amount of FAC detected did not differ significantly between hearts treated with FU (Tris) vials at 180 mg kg' b.w. and those treated with oxazolidine 2 at a dose equivalent to that injected with FU Tris vials for a dose of 180 mg FU kg-' b.w. In FU NaOH vials, we could identify Facet, and many unidentified fluorinated impurities were also detected.
These impurities are degradation products of FU, which form during storage in basic medium. To our knowledge, there are no detailed reports of the stability of FU or of identification of its products of decomposition. However, it has been reported that FU degrades more rapidly in alkaline than in weakly acidic conditions (Garrett et al., 1968; Tomankova & Zyka, 1977) . In preliminary experiments, we examined the stability of FU at a concentration of 50mg ml-' in Tris solution (1 M) at pH 8.5 and 25°C (data not shown). The signals at -122.3 and -125.9 ppm were detected within 4 days after dissolving FU powder in Tris; by day 14, we also observed the signals of fluoride ion and the compounds resonating at -117.2 and -124.8 ppm, and by day 20, the signal of the oxazolidine 2. A more detailed study of the mechanism of the alkaline hydrolysis of FU is in progress. The decomposition of FU in alkaline medium which is required for solubilisation leads to a compound that is metabolised to highly toxic FAC (LD 50 = 0.1-7.5 mg kg-' b.w. depending on the species (Meldrum & Bignell, 1957) ). FAC exerts specific actions on the myocardium and nervous system causing ventricular fibrillation and/or convulsions (Chenoweth & Gilman. 1946) . To avoid any possibility of chemical degradation, the solution of FU should be prepared immediately before injection. Modification of the manufacturing procedure for FU vials (a lyophilised form for example) should help limit the cardiotoxicity (and maybe also the neurotoxicity) of this drug.
FAC was consistently detected in the urine of patients treated with high doses of FU Tris Roche, the only formulation and brand available in France. There appeared to be no relationship, however, between urinary levels and clinical cardiotoxic symptoms. Various factors could account for this. Variations in the amounts of FAC, either from differences in amounts of Facet injected depending on the injected batch, or from individual differences in metabolising Facet or in defluorinating FAC, the main metabolic pathway of FAC detoxification (Mead et al., 1979; Tecle & Casida, 1989) , the existence of underlying myocardial disease could account for the incidence of ;10% reported for FU-related cardiotoxicity in most clinical studies. We noticed an increase in the daily urinary excretion of FAC during perfusion of FU in five out of the six patients studied (Figure 3 ). This could account for one of the striking features of FU cardiotoxicity namely the delayed onset with respect to the beginning of the treatment of clinical cardiotoxic symptoms (Collins & Weiden, 1987; Freeman & Costanza, 1988; de Forni et al., 1990; .
Although our results are preliminary, we did observe differences in cardiotoxic effects and citrate levels between the German, English and American FU NaOH vials (Table II) . Since the '9F NMR spectra from these formulations are similar but very complex, we cannot readily account for these diverse data. Work is in progress to elucidate the matter.
